Pharmaceutical transport management system and transport management method

Abstract

The present invention provides a pharmaceutical transport management system and a pharmaceutical transport management method that can reliably determine the suitability of the returned pharmaceuticals themselves. [Solution] The pharmaceutical transport management system 1 includes a logger 3 that records the temperature inside the transport container 2, an individual identifier 4 that identifies product information including shipment information of pharmaceutical X, a quality information management unit 10 that manages the information from the logger 3, a manufacturing information (shipment information) management unit 20 that manages the information from the individual identifier 4, and a suitability evaluation unit 30 that evaluates the suitability of pharmaceutical X.

Description

TECHNICAL FIELD

[0001] The present invention relates to a pharmaceutical transport management system and a pharmaceutical transport management method for transporting pharmaceuticals to medical institutions via transport containers that maintain the pharmaceuticals within a specific temperature range.

BACKGROUND ART

[0002] As disclosed in Patent Document 1 below, there is known a cold insulation box that includes a storage section capable of storing contents, a lid section covering the opening of the storage section, and a cold insulation device for keeping the storage section cool. The cold insulation box is equipped with an RF tag with a temperature sensor provided on the contents, a first antenna section disposed inside the storage section, a second antenna section disposed on the inner surface side of the lid section, and a control section. The control section communicates with the RF tag of the contents stored in the storage section via the first antenna section at appropriate time intervals, stores the ID information of the RF tag and the temperature information sensed by the temperature sensor of the RF tag, and when the lid section is in an open state, communicates with the RF tag of the contents moving into and out of the storage section via the second antenna section, and stores the ID information of the RF tag and entry / exit time information.

[0003] In such a cold insulation box, an upper limit temperature and a time limit are set. It is detected that the temperature information of the contents is equal to or higher than the upper limit temperature, and when the duration of such a state exceeds the time limit, a notification is transmitted to an external terminal via the control section.

[0004] Furthermore, Patent Document 1 discloses a configuration in which, in a cold insulation box management system for managing such cold insulation boxes, the cold insulation boxes are conveyed on a belt conveyor, a temperature management device receives the temperature information of each content stored in the conveyed cold insulation boxes, and when it is determined through collation that the temperature information has ever exceeded the set upper limit temperature, the temperature management device controls to sort the cold insulation boxes.

[0005] Furthermore, Patent Document 2 provides a temperature control device installed in a storage box for storing articles subject to temperature control, comprising: an article ID storage unit that stores an article ID to identify the article; a temperature control unit that detects the ambient temperature of the article inside the storage box at regular intervals using a temperature sensor and generates temperature data including the ambient temperature, article ID, and measurement time; a set temperature condition storage unit that stores the upper and lower limits of the ambient temperature as set temperature conditions; a temperature abnormality determination unit that compares the ambient temperature included in the temperature data with the set temperature conditions and determines whether or not there is a temperature abnormality; an elapsed time measurement unit that measures the elapsed time since the article was removed from the storage box based on the detection result of a tag attached to the article; a set time condition storage unit that stores the upper limit of the elapsed time as a set time condition; and a time abnormality determination unit that compares the elapsed time with the set time conditions and determines whether or not there is a time abnormality.

[0006] Furthermore, Patent Document 3 describes a delivery system for goods requiring refrigeration, comprising: a delivery packing facility that packages goods requiring refrigeration in a reusable insulated box along with reusable cooling materials to constitute the delivery goods; a delivery facility that collects the packed delivery goods and delivers them to customers; a recycling facility that recycles used cooling materials and insulated boxes for reuse; and a stock facility for the recycled cooling materials and insulated boxes. The system comprises a delivery route from the delivery packing facility through the delivery facility to the customer, a collection route for used cooling materials and insulated boxes from the customer side through the delivery facility to the recycling facility, and a replenishment route for recycled cooling materials and insulated boxes from the recycling facility through the stock facility to the delivery packing facility. [Prior art documents] [Patent Documents]

[0007] [Patent Document 1] Japanese Patent Publication No. 2019-031308 [Patent Document 2] Japanese Patent Publication No. 2016-204094 [Patent Document 3] Japanese Patent Publication No. 2005-289606 [Overview of the project] [Problems that the invention aims to solve]

[0008] However, the systems described in Patent Documents 1 to 3 above are intended for temperature control of items that require temperature control, and it is difficult to determine the suitability of the temperature-controlled pharmaceuticals themselves when they are returned.

[0009] In view of the above circumstances, the present invention aims to provide a pharmaceutical transport management system and a pharmaceutical transport management method that can reliably determine the suitability of the returned pharmaceuticals themselves. [Means for solving the problem]

[0010] The pharmaceutical transport management system of the first invention is a pharmaceutical transport management system that transports pharmaceuticals to medical institutions via transport containers that maintain a specific temperature range, A logger is provided in the transport container to record the elapsed time and temperature changes since shipment, The individual identifier attached to the aforementioned pharmaceutical product and linked to the shipping information, When the aforementioned pharmaceutical product is returned without being used, a suitability evaluation unit reads the elapsed time and temperature changes recorded in the logger, and refers to the shipping information associated with the individual identifier to evaluate the suitability of the pharmaceutical product. It is characterized by having the following features.

[0011] According to the pharmaceutical transport management system of the first invention, when a pharmaceutical product is returned unused, the suitability evaluation unit reads the elapsed time and temperature changes recorded in the logger, and then refers to the shipping information linked to the individual identifier to evaluate the suitability of the pharmaceutical product.

[0012] Therefore, (not only in terms of temperature control for items requiring temperature control, but also in terms of the return of pharmaceuticals themselves that require temperature control, it is possible to determine whether the manufacturing control methods, including shipping information, and the quality control methods, including temperature control, meet the suitability standards for the pharmaceuticals, based on the shipping information, the elapsed time since shipping recorded in the logger, and the temperature changes.

[0013] Thus, according to the pharmaceutical transport management system of the first invention, the suitability of the returned pharmaceutical product itself can be reliably determined.

[0014] The pharmaceutical transport management system of the second invention is, in the first invention, The conformity evaluation unit is characterized by making a reshipment determination based on whether the reshipment conditions, which are set based on either or both of the elapsed time and temperature change recorded in the logger and the shipping information associated with the individual identifier, are met.

[0015] According to the pharmaceutical transport management system of the second invention, in the assessment of suitability, a reshipment decision is made based on whether the reshipment conditions are met. This makes it possible to reship pharmaceuticals that meet the reshipment conditions, and significantly reduces the waste of pharmaceuticals.

[0016] Thus, according to the pharmaceutical transport management system of the second invention, the suitability of the returned pharmaceutical product itself can be reliably determined to determine its eligibility for reshipment.

[0017] According to the pharmaceutical transport management system of the third invention, in the second invention, The conformity evaluation unit is characterized by recommending a reshipment destination based on the satisfaction of the reshipment conditions when it is determined in the reshipment determination that reshipment is possible.

[0018] According to the pharmaceutical transport management system of the third invention, a reshipment destination is recommended based on the satisfaction of reshipment conditions. Accordingly, when the satisfaction of reshipment conditions is high, for example, when a long transport time can still be secured, a distant reshipment destination or a reshipment destination with a late scheduled use date is recommended. On the other hand, when the satisfaction of reshipment conditions is not very high, for example, when the transport time is limited, a nearby reshipment destination or a reshipment destination with an early scheduled use date is recommended. Therefore, it is possible to select the reshipment destination of the pharmaceutical product according to the appropriateness of reshipment, and the disposal of pharmaceutical products can be further significantly reduced.

[0019] As described above, according to the pharmaceutical transport management system of the third invention, it is possible to reliably determine the eligibility for reshipment as the suitability of the returned pharmaceutical product itself, including the appropriateness of reshipment.

[0020] The pharmaceutical transport management system of the fourth invention is the system according to any one of the first to third inventions, wherein the logger issues a notification when a deviation from the specific temperature range has lasted for a predetermined period of time.

[0021] According to the pharmaceutical transport management system of the fourth invention, by issuing a notification via the logger when a deviation from the specific temperature range has lasted for a predetermined period of time, pharmaceutical products that lack suitability can be excluded in advance.

[0022] As described above, according to the pharmaceutical transport management system of the fourth invention, by excluding pharmaceutical products that are clearly unsuitable in advance, the suitability of the returned pharmaceutical product itself can be reliably determined.

[0023] The pharmaceutical transport management method of the fifth invention is a pharmaceutical transport management method for transporting a pharmaceutical product to a medical institution via a transport container that keeps the pharmaceutical product in a specific temperature range, the method comprising: a logger provided in the transport container for recording the elapsed time since shipment and temperature changes; an individual identifier attached to the pharmaceutical product and associated with shipment information; and Therefore, when the pharmaceutical product is returned without being used, a suitability assessment process is performed in which the suitability of the pharmaceutical product is evaluated by reading the elapsed time and temperature changes recorded in the logger and referring to the shipping information associated with the individual identifier.

[0024] According to the pharmaceutical transport management method of the fifth invention, in the suitability evaluation step, when a pharmaceutical is returned without being used, the suitability of the pharmaceutical is evaluated by reading the elapsed time and temperature changes recorded in the logger and referring to the shipping information linked to the individual identifier.

[0025] Therefore, (not only in terms of temperature control for items requiring temperature control, but also in terms of the return of pharmaceuticals themselves that require temperature control, it is possible to determine whether the manufacturing control methods, including shipping information, and the quality control methods, including temperature control, meet the suitability standards for the pharmaceuticals, based on the shipping information, the elapsed time since shipping recorded in the logger, and the temperature changes.

[0026] Thus, according to the pharmaceutical transport management method of the fifth invention, the suitability of the returned pharmaceutical itself can be reliably determined. [Brief explanation of the drawing]

[0027] [Figure 1] A diagram showing the configuration of the pharmaceutical transport management system of this embodiment. [Modes for carrying out the invention]

[0028] In this specification, pharmaceuticals include pharmaceuticals, medical devices, quasi-drugs, cosmetics, drugs, chemicals, reagents, etc., as defined by the regulatory laws of each country. In the present invention, the pharmaceutical is preferably a pharmaceutical or medical device as defined by the regulatory laws of each country, and more preferably a medical device.

[0029] Examples of pharmaceutical embodiments described herein include, for example, vaccines, blood products, biopharmaceuticals, and biomaterials, with biomaterials being preferred. Another embodiment of a pharmaceutical product as described herein is, for example, a pharmaceutical product and / or medical device that requires cold storage and is capable of being maintained at a specific temperature range (e.g., 0-10°C, 1-30°C, 15-25°C, 1-15°C, 2-8°C, etc.) for a specific time (e.g., 50 hours, 100 hours, 150 hours, 200 hours, etc.). Examples of pharmaceutical forms used herein include eye drops, suppositories, injections, solutions, ointments, pre-filled syringes, kits, and hydrogels, with injections, solutions, pre-filled syringes, kits, or hydrogels being preferred. Examples of pharmaceutical ingredients in this specification include polysaccharides such as sodium hyaluronate and sodium alginate, proteins such as collagen, antibiotics, hormones, enzymes, antigens, and antibodies.

[0030] As shown in Figure 1, the pharmaceutical transport management system 1 of this embodiment is a system operated by, for example, a pharmaceutical company that manufactures and sells pharmaceutical X, and manages the transport between the manufacturer and the shipping source of the transport container 2 that keeps pharmaceutical X at a specific temperature range and a medical institution Y.

[0031] The pharmaceutical transport management system 1 includes a logger 3 that records the temperature inside the transport container 2, an individual identifier 4 that identifies product information including shipment information of pharmaceutical X, a quality information management unit 10 that manages the information from the logger 3, a manufacturing information (shipment information) management unit 20 that manages the information from the individual identifier 4, and a conformity evaluation unit 30 that evaluates the conformity of pharmaceutical X.

[0032] The pharmaceutical product X described in this embodiment means the pharmaceutical product defined or exemplified above. In particular, in this embodiment, when unused pharmaceutical product X is returned from medical institution Y to the manufacturer / distributor after being maintained at a specific temperature range for a specific time, its suitability (quality control and manufacturing control) is determined, and it is then eligible for reshipment. This enables the business of lending temperature-controlled products (pharmaceutical product X and its transport container 2). If the specific temperature range in this embodiment is low temperature (for example, 0-10°C, 2-8°C, etc.), the entire transport container 2 is lent to medical institution Y, eliminating the need to secure temperature-controlled space (refrigerator, etc.) at medical institution Y.

[0033] If the specific temperature range of this embodiment is to be kept low (for example, 0-10°C, 2-8°C, etc.), it is preferable to transport the transport container 2 itself under low-temperature control (so-called refrigerated transport, etc.) during round-trip transport. The transport container 2 is a so-called insulated box, and a cooler box with a vacuum insulation structure that has a high cooling and heat retention effect is preferred. Examples of transport containers 2 include Cool One, V-BOX (both manufactured by Wacon Co., Ltd.), and HUGEL vacuum insulated cooler box (manufactured by Iris Ohyama Co., Ltd.). When the transport container 2 is sealed with the pharmaceutical X inside, a cooling and heat retention material (heat storage material) for maintaining the specific temperature range is also stored inside. The number of pharmaceutical X stored in the transport container 2 is not particularly limited, but it is preferable that one pharmaceutical X is stored in each transport container 2. The size, number, and arrangement of the cooling and heat retention material (heat storage material) stored in the transport container 2 are not particularly limited, but it is preferable that it be arranged to surround the pharmaceutical X. For example, PCM-PAC (manufactured by Nippon Blower Co., Ltd.), Ecojoule (manufactured by ENEOS Sun Energy Co., Ltd.), ThermoCatch (manufactured by Wacon Co., Ltd.), and Chiltein (manufactured by Ice Japan Co., Ltd.) can be used as cooling and heat retention materials (heat storage materials).

[0034] Logger 3 is positioned inside the transport container 2 adjacent to the pharmaceutical product X and continuously records the ambient temperature of the pharmaceutical product X inside the transport container 2 at predetermined intervals. As shown in Figure 1, the logger 3 itself may be housed inside the transport container 2, or the temperature sensor may be installed near the pharmaceutical product X inside the transport container 2, with the display unit of the logger 3 visible from outside the transport container 2. Examples of logger 3 include a temperature and humidity data logger (manufactured by AS ONE Corporation) and a temperature data logger (manufactured by Fujita Electric Works Co., Ltd.). The recorded temperature data is read and managed by the quality information management unit 10 as elapsed time and temperature change since shipment. The temperature data may be read by contact via a wired cable or by non-contact via a sensor or communication device.

[0035] Furthermore, Logger 3 is equipped with an alarm function. For example, if the temperature exceeds a specific temperature range (e.g., 10.1°C) for a certain period of time (e.g., 20 minutes or more), an alert mark will be displayed on Logger 3's display, and if a speaker is provided, an alarm will be broadcast from the speaker.

[0036] The individual identifier 4 is an ID for individual management of pharmaceutical X in manufacturing control, and consists of a tag (RFID tag) that identifies shipping information including the shipping time, as well as a barcode or QR code (registered trademark), in addition to manufacturing traceability. The management of information on the individual identifier 4 (management of the ID and the manufacturing information corresponding to the ID) is performed by the manufacturing information management unit 20. The individual identifier 4 may be assigned to pharmaceutical X itself, or, as shown in Figure 1, it may be assigned to the transport container 2 in which pharmaceutical X is stored.

[0037] The quality information management unit 10 is a processing unit that performs quality control on pharmaceutical product X, and primarily reads and records temperature data recorded by the logger 3.

[0038] The manufacturing information management unit 20 is a processing unit that performs manufacturing management, including shipment information for drug X, and primarily records manufacturing management information corresponding to the individual identifier (ID) 4. More specifically, by recording manufacturing management information linked to the individual identifier 4, the manufacturing information management unit 20 can record and manage, for example, the time elapsed since the manufacture of drug X, the time elapsed since arrival, the time elapsed since the first shipment, the number of shipments, etc.

[0039] The conformity assessment unit 30 evaluates the conformity of drug X by referring to the elapsed time and temperature change temperature data recorded in the logger 3, which is read via the quality information management unit 10 when drug X is returned unused, and the shipment information of the individual identifier 4 managed by the manufacturing information management unit 20.

[0040] Further details regarding the processing performed by the Quality Information Management Department 10, the Manufacturing Information Management Department 20, and the Conformity Assessment Department 30 will be described later.

[0041] The above describes the configuration of the pharmaceutical transport management system 1 of this embodiment. In the above configuration, each processing unit 10 to 30 is composed of hardware such as a CPU (Central Processing Unit), ROM (Read Only Memory), and RAM (Random Access Memory), respectively, and stores a program that executes various processes described later in memory (not shown), and functions as a calculation unit (sequencer) for executing various processes by executing that program. Alternatively, some or all of the processing units 10 to 30 may be composed of other servers (external servers), and the pharmaceutical transport management system 1 may be realized through distributed processing.

[0042] Next, we will explain the pharmaceutical transportation management method using the pharmaceutical transportation management system 1.

[0043] First, when a pharmaceutical company or other manufacturer receives notification from medical institution Y that it plans to use drug X, the manufacturer places drug X in transport container 2, seals it with insulating material (heat storage material) to maintain a specific temperature range, and ships it to medical institution Y, according to the planned date and time of use.

[0044] At this time, the quality information management unit 10 identifies and records the logger 3, which is stored in the transport container 2 together with the drug X, using the individual identifier (ID) 4 of the drug X. The logger 3 starts recording temperature data from the moment the drug X is placed in the transport container 2 (the moment it is placed and sealed, which is the same as the time of shipment).

[0045] Furthermore, the manufacturing information management unit 20 identifies and records the individual identifier (ID) 4 attached to the transport container 2, which is capable of identifying the manufacturing and shipping information of the pharmaceutical product X.

[0046] If the drug X shipped in this manner is used at medical institution Y, the transport container 2 will be opened, the drug X will be used, and only the transport container 2 will be returned to the manufacturer. However, if the drug X is not used at medical institution Y, the drug X will be returned to the manufacturer along with the transport container 2, while being maintained at a specific temperature range.

[0047] When drug X remains unused and is returned to the manufacturer, the Quality Information Management Unit 10 reads temperature data from the logger 3, and the Manufacturing Information Management Unit 20 reads the shipping information (shipping date and time, etc.) of drug X, which is identified by its individual identifier (ID) 4.

[0048] Then, the conformity evaluation unit 30 performs the conformity evaluation process.

[0049] In the conformity assessment process performed by the conformity assessment unit 30, the unit evaluates whether the temperature data (elapsed time since shipment and temperature change) read by the quality information management unit 10 deviates from a specific temperature range, and if there is a deviation, it evaluates the degree of that deviation.

[0050] In this case, if a deviation from a specific temperature range occurs for a predetermined period of time via logger 3, an alert is displayed on the logger 3's display unit in advance, making it possible to preemptively eliminate drug X that is unsuitable.

[0051] The degree of deviation is assessed by calculating the cumulative time spent above the upper limit temperature of a specific temperature range, as well as whether or not a threshold temperature set higher than the upper limit temperature (e.g., 30°C) or lower than the lower limit temperature (e.g., -10°C) is reached.

[0052] Furthermore, in the conformity assessment process performed by the conformity assessment unit 30, the remaining time for a specific period (e.g., 200 hours) is calculated by referring to the expiration date and shipping information (shipping date and time, etc.) from the manufacturing information of the drug X identified by the individual identifier (ID) 4 by the manufacturing information management unit 20.

[0053] Based on these conformity evaluation processes, the conformity evaluation unit 30 refers to the reshipment conditions and performs a reshipment determination process based on whether those conditions are met.

[0054] In the reshipment determination process by the conformity evaluation unit 30, if (1-A) there is no deviation from the specified temperature range (here, for example, 1 to 10°C), or (1-B) even if there is a deviation, the degree of the deviation is small (for example, the threshold temperature (for example, 30°C) is not reached, and the temperature above the specified temperature range (for example, 10.1°C) is less than half of the assumed cumulative time (for example, 20 minutes)), the product is deemed to meet quality conformity and is subject to reshipment on the condition that the following manufacturing conformity is met.

[0055] Furthermore, in the reshipment determination by the conformity evaluation unit 30, the remaining time for a specific time (e.g., 200 hours) is (2-A) sufficient (e.g., 120 hours or more), (2-B) somewhat sufficient (e.g., 80 hours to 120 hours), or (2-C) present (e.g., 50 hours to 80 hours) if it meets the manufacturing conformity criteria and is subject to reshipment.

[0056] Furthermore, in the reshipment determination process described above, the conformity evaluation unit 30 recommends a reshipment destination that satisfies the reshipment conditions. The satisfaction of the reshipment conditions is determined by whether the quality conformity rank is A rank (1-A) or B rank (1-B), and whether the manufacturing conformity rank is A rank (2-A), B rank (2-B), or C rank (2-C).

[0057] The conformity evaluation unit 30, for example, if the quality conformity rank is A rank (1-A) and the manufacturing conformity rank is A rank (2-A), and the satisfaction of the reshipment conditions is high, recommends a medical institution Y' that is a distant reshipment destination or a reshipment destination with a later planned use, as it is a case where there is still a long period of time available for transportation.

[0058] On the other hand, if the suitability assessment unit 30 determines that the satisfaction of the reshipment conditions is not very high, for example, when the quality suitability rank is B (1-B) and the manufacturing suitability rank is C (2-C), it will recommend a nearby medical institution Y' for reshipment, or a medical institution with an early planned use, assuming that transportation time will be limited.

[0059] Furthermore, the conformity evaluation unit 30 recommends an intermediate position or a medical institution Y' which is the intended recipient of the reshipment, in cases where the satisfaction of the reshipment conditions is high or not so high (for example, when the quality conformity rank is B rank (1-B) and the manufacturing conformity rank is B rank (2-B)).

[0060] Thus, according to the pharmaceutical transportation management system 1, it becomes possible to select a reshipping destination for pharmaceutical X according to the appropriateness of reshipment, thereby promoting the reuse of pharmaceutical X and further significantly reducing the waste of pharmaceutical X.

[0061] As explained in detail above, the pharmaceutical transport management system 1 of this embodiment can reliably determine the suitability of the returned pharmaceutical X itself for reshipment, including the appropriateness of the reshipment.

[0062] In this embodiment, we have described a case where the logger 3 provides notification (alert display or alarm notification) when the temperature exceeds a specific temperature range (e.g., 10.1°C) for a certain period of time (e.g., 20 minutes) or longer. However, the notification trigger and notification means are not limited to this. For example, the notification trigger may be when the temperature exceeds a specific temperature range (e.g., 10.1°C) or higher, and the notification means may be that the logger 3 communicates with the pharmaceutical transportation management system 1 (quality information management unit 10), and the pharmaceutical transportation management system 1 sends a notification (email or SMS) to the medical institution Y or the transportation company. [Explanation of Symbols]

[0063] 1...Pharmaceutical transport management system, 2...Transport container, 3...Logger, 4...Individual identifier, 10...Quality information management department, 20...Manufacturing information (shipping information) management department, 30...Conformity assessment department, X...Pharmaceuticals, Y...Medical institution (shipping destination), Y'...Medical institution (reshipping destination).

Claims

1. A pharmaceutical transport management system that transports pharmaceuticals to medical institutions via transport containers that maintain a specific temperature range, A logger is provided in the transport container to record the elapsed time and temperature changes since shipment, The individual identifier attached to the aforementioned pharmaceutical product and linked to the shipping information, When the aforementioned pharmaceutical product is returned without being used, a suitability evaluation unit reads the elapsed time and temperature changes recorded in the logger, and refers to the shipping information associated with the individual identifier to evaluate the suitability of the pharmaceutical product. A pharmaceutical transportation management system characterized by having the following features.

2. In the pharmaceutical transport management system according to claim 1, The pharmaceutical transport management system is characterized in that the conformity evaluation unit makes a reshipment determination based on whether the reshipment conditions, which are set based on either or both of the elapsed time and temperature change recorded in the logger and the shipping information linked to the individual identifier, are met.

3. In the pharmaceutical transport management system according to claim 2, The pharmaceutical transportation management system is characterized in that, when the suitability evaluation unit determines that reshipment is possible in the reshipment determination, it recommends a reshipment destination based on the satisfaction of the reshipment conditions.

4. In a pharmaceutical transport management system according to any one of claims 1 to 3, The pharmaceutical transport management system is characterized in that the logger notifies when the temperature deviates from the specified temperature range for a predetermined period of time.

5. A method for managing the transportation of pharmaceuticals, which involves transporting pharmaceuticals to medical institutions via transport containers that maintain a specific temperature range, A logger is provided in the transport container to record the elapsed time and temperature changes since shipment, The individual identifier attached to the aforementioned pharmaceutical product and linked to the shipping information and A method for managing the transportation of pharmaceuticals, characterized in that, when the pharmaceuticals are returned without being used, a suitability evaluation step is performed in which the suitability of the pharmaceuticals is evaluated by reading the elapsed time and temperature changes recorded in the logger and referring to the shipping information linked to the individual identifier.

Images